Veracyte (VCYT) Net Income towards Common Stockholders (2012 - 2026)

Veracyte has reported Net Income towards Common Stockholders for 15 years, with the latest figure at $25.5 million in Q2 2026.

• Net Income towards Common Stockholders for Q2 2026 came in at $25.5 million, up 2701.02% year-over-year; the trailing twelve-month figure through Jun 2026 was $114.5 million (up 334.77% YoY), and the FY2025 annual result was $66.4 million, up 174.89% from the prior year.
• Net Income towards Common Stockholders retreated to $25.5 million in Q2 2026, from $28.7 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $41.2 million in Q4 2025 and troughed at -$29.6 million in Q3 2023.
• A 5-year average of $1.9 million and a median of -$1.4 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• The widest annual swing landed in 2023, when Net Income towards Common Stockholders plunged 630.33%; it then surged 2701.02% in 2026.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$3.9 million in 2022, then plunged by 630.33% to -$28.3 million in 2023, then jumped by 118.16% to $5.1 million in 2024, then jumped by 701.75% to $41.2 million in 2025, then tumbled by 38.11% to $25.5 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $25.5 million in Q2 2026, $28.7 million in Q1 2026, and $41.2 million in Q4 2025.